The development of a diphtheria anti-toxin serum was a race between researchers
Emil Behring in Berlin, and Émile Roux in Paris. They both developed it nearly simultaneously. However, the serum was marketed differently in each country. In Germany, the serum was marketed in a private business setting, whereas in France, the serum was distributed through a communal health care system. The race to develop the
diphtheria anti-toxin serum was considered a national rivalry, although each team of researchers adopted each other's experimental practices and built off of each other. In a controversy, the first
Nobel Prize for Physiology and Medicine was given to Emil Von Behring for his work on the serum therapy for diphtheria. Roux had been nominated in 1888 for the isolation of the diphtheria toxin, but didn't win the prize in 1901 because his discovery was deemed to be too "old." Over the years, Roux came close to the Nobel Prize but never won. Also in 1883, Roux published, with
Alexandre Yersin, the first of his classical works on the causation of
diphtheria by the
Klebs-Loeffler bacillus, then an extremely prevalent and lethal disease, particularly among children.
Diphtheria is contagious microbial disease marked by throat lesions,
polyneuritis,
myocarditis,
low blood pressure, and collapse. He studied its toxin and its properties, and began in 1891 to develop an effective serum to treat the disease, following the demonstration, by
Emil Adolf von Behring (1854–1917) and
Kitasato Shibasaburō (1852–1931) that
antibodies against the diphtheric toxin could be produced in animals. He successfully demonstrated the use of this antitoxin with
Auguste Chaillou in a study with 300 diseased children in the
Hôpital des Enfants-Malades and was henceforth hailed as a scientific hero in medical congresses throughout Europe. ==Other research and later years==